U.S. federal trademark · Serial No. 99208514
patient and caregiver support services and medical information relating to spinal muscular atrophy (SMA), apitegromab preparations, case management, financial assistance, copay support, reimbursement support, drug access, patient and caregiver education, and support for infusions and infusion logistics
research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products
Monoclonal antibodies for medical purposes; pharmaceutical preparations, namely, antibodies for the treatment of spinal muscular atrophy (SMA); therapeutic preparations comprising apitegromab, being a monoclonal antibody for the treatment of spinal muscular atrophy (SMA), musculoskeletal disorders, neuromuscular diseases and disorders, genetic diseases and disorders, and neurological diseases and disorders; therapeutic agents and pharmaceutical preparations for the treatment of musculoskeletal disorders, neuromuscular diseases and disorders, genetic diseases and disorders, and neurological diseases and disorders
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.